Biological Dynamics Announces Early Access Program to Its ExoVerita™ Pro Platform

Easy-to-use, proprietary technology platform transforms exosome research by automating isolation and accelerating exosome-derived insights into human health and disease

SAN DIEGO – Nov. 8, 2023 – Biological Dynamics, Inc., the leader in exosome-isolation technology, today announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.

“Technology is revolutionizing our understanding and management of some of our most challenging diseases,” said Paul R. Billings, M.D., Ph.D., CEO and Director of Biological Dynamics. “Data suggests that exosomes play an important role in human health and in decoding diseases. Providing researchers with a more reliable, rapid, and easy-to-use option for capturing exosomes brings us closer to our corporate mission: never diagnosing a disease too late.”

Extracellular vesicles, including exosomes, are continually released from cells and carry information that can indicate the presence of disease, including cancer. Isolating exosomes using previously available methods poses purity, reproducibility, and other challenges. Biological Dynamics’ ExoVerita technology platform offers an automated workflow for successfully detecting and recovering exosomes that have benefits over other methods, such as ultracentrifugation and column purification. ExoVerita Pro provides high purity and yields while being fast and effective, enabling greater productivity through reduced hands-on time.

The company’s lab-on-a-chip platform leverages AC Electrokinetics (ACE) technology for isolating exosomes from biofluids such as whole blood, plasma, and serum. Following exosome enrichment with the ExoVerita Pro, researchers can use the collected material for experiments, including amplification and sequencing of DNA, RNA analysis, and measurement of exosome protein concentration. This information can be used to accelerate understanding of the effectiveness of new drugs under development, develop tests for diagnosis and prognosis of disease, as well as many other applications.

Biological Dynamics will showcase its Early Access Program and products at the Association for Molecular Pathology (AMP) Annual Meeting in Salt Lake City, Utah, Nov. 14-18, and will debut ExoVerita Pro at the SelectBio Conference in Laguna Hills, Calif., Nov. 28-30.

About Biological Dynamics

Biological Dynamics, Inc. is committed to improving global health outcomes by detecting diseases at the earliest stages. Its proprietary exosome-isolation ExoVerita™ platform, currently used by the company and research customers, simplifies the isolation of extracellular vesicles, enabling multiomic applications. Biological Dynamics recently initiated its ExoLuminate study, a clinical trial to demonstrate the effectiveness of its ExoVita™ Pancreas assay for early-stage detection of pancreatic cancer. The Company operates a CAP-accredited, CLIA-certified clinical laboratory in San Diego. Learn more at www.ExoLuminate.com.